AGIOS PHARMACEUTICALS, INC. (AGIO)

28.2 0.36 (1.29%)

As of 2025-12-02 08:00:28 EST

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.: Table 1

Traded asNasdaq: AGIO
ISINUS00847X1046
CIK0001439222
LEI529900ONJHY8EOGYT555
EIN—
Sector—
IndustryPharmaceutical Preparations
CEOBrian Goff
Employees536
Fiscal Year End1231
Address88 SIDNEY STREET, CAMBRIDGE, MA, 02139
Phone617-649-8600
Websitehttp://agios.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
AGIOAGIOS PHARMACEUTICALS, INC.2025-12-02 08:00:2828.20.361.29
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
AGIO0001439222AGIOS PHARMACEUTICALS, INC.US00847X1046529900ONJHY8EOGYT555—Nasdaq2834Pharmaceutical Preparations1231DE88 SIDNEY STREETCAMBRIDGEMA02139UNITED STATESUS617-649-860088 SIDNEY STREET, CAMBRIDGE, MA, 0213988 SIDNEY STREET, CAMBRIDGE, MA, 02139AGIOS PHARMACEUTICALS INC—2008Brian Goff536http://agios.com2,416,161,20074,496,28758,313,812Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.: Table 12025-11-27 16:52:21
This is a preview of the latest data. Subscribe to access the full data.
AGIO Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
AGIO Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20242,416,161,200858,375,87455.102357,296,1671,101,3201.9598
20231,557,785,326357,507,82229.785456,194,847909,6241.6453
20221,200,277,504-2,067,312,497-63.267255,285,223647,7221.1855
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
James BurnsChief Legal Officer2024511,9170548,590287,95415,8612,432,507
Sarah GheuensChief Medical Officer2024583,4950548,590328,21615,8612,544,347
Brian GoffChief Executive Officer2024822,19801,742,580719,42311,6536,776,359
Cecilia JonesChief Financial Officer2024503,8800548,590283,43315,2612,419,349
Tsveta MilanovaChief Commercial Officer2024525,3000548,590295,48215,8612,453,418
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2024486
2023383
2022389
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue36,498,00026,823,00014,240,000
Cost Of Revenue4,165,0002,881,0001,704,000
Gross Profit———
Research And Development Expenses301,286,000295,526,000279,910,000
General And Administrative Expenses156,784,000119,903,000121,673,000
Operating Expenses462,235,000418,310,000403,287,000
Operating Income-425,737,000-391,487,000-389,047,000
Net Income673,725,000-352,088,000-231,801,000
Earnings Per Share Basic11.86-6.33-4.23
Earnings Per Share Diluted11.64-6.33-4.23
Weighted Average Shares Outstanding Basic56,807,41555,651,48754,789,435
Weighted Average Shares Outstanding Diluted57,889,25555,651,48754,789,435
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents76,247,00088,205,000139,259,000
Marketable Securities Current817,463,000688,723,000643,860,000
Accounts Receivable4,109,0002,810,0002,206,000
Inventories27,616,00019,076,0008,492,000
Non Trade Receivables900,0001,100,000300,000
Other Assets Current———
Total Assets Current965,600,000833,835,000832,772,000
Marketable Securities Non Current638,321,00029,435,000313,874,000
Property Plant And Equipment11,675,00015,382,00022,987,000
Other Assets Non Current4,724,0004,057,0003,956,000
Total Assets Non Current697,599,000103,283,000405,946,000
Total Assets1,663,199,000937,118,0001,238,718,000
Accounts Payable16,643,0009,780,00018,616,000
Deferred Revenue———
Short Term Debt———
Other Liabilities Current46,861,00043,167,00030,350,000
Total Liabilities Current81,156,00067,955,00062,629,000
Long Term Debt———
Other Liabilities Non Current880,0001,156,0003,279,000
Total Liabilities Non Current41,087,00058,144,00075,275,000
Total Liabilities122,243,000126,099,000137,904,000
Common Stock73,00072,00071,000
Retained Earnings-148,924,000-822,649,000-470,561,000
Accumulated Other Comprehensive Income———
Total Shareholders Equity1,540,956,000811,019,0001,100,814,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization5,700,0006,600,0008,400,000
Share Based Compensation Expense42,847,00044,766,00049,296,000
Other Non Cash Income Expense39,000-553,00048,000
Change In Accounts Receivable1,299,000604,0002,206,000
Change In Inventories8,540,00010,584,0008,492,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable6,601,000-8,733,0003,436,000
Change In Other Liabilities-276,000-2,123,0003,003,000
Cash From Operating Activities-389,841,000-296,062,000-309,478,000
Purchases Of Marketable Securities1,542,433,000417,930,0001,030,781,000
Sales Of Marketable Securities818,383,000674,679,0001,146,175,000
Acquisition Of Property Plant And Equipment1,685,000999,0004,881,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities363,441,000239,575,000243,261,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock———
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities14,442,0005,433,0002,681,000
Cash From Financing Activities14,442,0005,433,0002,350,000
Change In Cash-11,958,000-51,054,000-63,867,000
Cash At End Of Period76,247,00088,205,000139,259,000
Income Taxes Paid43,150,0001,569,0000
Interest Paid———
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share11.86-6.33-4.23
Price To Earnings Ratio2.7707-3.5182-6.6383
Earnings Growth Rate-287.361849.6454-115.9322
Price Earnings To Growth Ratio-0.0096-0.07090.0573
Book Value Per Share27.12614.573220.0917
Price To Book Ratio1.21141.52811.3976
Ebitda722,575,000-343,919,000-223,401,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures1,993,000-1,005,0002,464,000
Free Cash Flow-391,834,000-295,057,000-311,942,000
Return On Equity0.4372-0.4341-0.2106
One Year Beta1.58391.13231.5315
Three Year Beta1.45471.28911.0379
Five Year Beta1.08271.09621.148
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Scadden DavidDirector2025-11-12200A17,803
Scadden DavidDirector2025-11-12200D17,603
Scadden DavidDirector2025-11-12200D26,907
Gheuens SarahChief Medical Officer2025-11-112,454A64,181
Gheuens SarahChief Medical Officer2025-11-112,454D61,727
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Gilbert Cisneros2025-05-06CA31Purchase2025-04-17—$1,001 - $15,000
Gilbert Cisneros2025-02-11CA31Purchase2025-01-29—$1,001 - $15,000
Josh Gottheimer2024-02-15NJ05Purchase2024-01-24Joint$1,001 - $15,000
Thomas MacArthur2015-06-07NJ03Sale2015-05-27Joint$1,001 - $15,000
Thomas MacArthur2015-04-11NJ03Purchase2015-03-18Joint$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Advisory Services Network, LLC2025-09-3014,04935040.14
Pictet Asset Management Holding SA2025-09-3010,694,859272,16139.2961
NewEdge Advisors, LLC2025-09-3051,0981,27340.1398
ARMISTICE CAPITAL, LLC2025-09-3030,666,960764,00040.14
ARMISTICE CAPITAL, LLC2025-09-3036,126,000900,00040.14
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
RYDEX SERIES FUNDS2025-09-30Class CRYCFX13,883557,263.620.6191
RYDEX SERIES FUNDS2025-09-30Class ARYBOX13,883557,263.620.6191
RYDEX SERIES FUNDS2025-09-30Class HRYOAX13,883557,263.620.6191
RYDEX SERIES FUNDS2025-09-30Investor ClassRYOIX13,883557,263.620.6191
RYDEX SERIES FUNDS2025-09-30Class CRYCMX793,171.060.0475
This is a preview of the latest data. Subscribe to access the full data.